标题
New Pharmacological Approaches to Target PCSK9
作者
关键词
-
出版物
Current Atherosclerosis Reports
Volume 22, Issue 7, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-04
DOI
10.1007/s11883-020-00847-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
- (2020) Peter G. Chandler et al. Cells
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
- (2019) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol metabolism, pancreatic β-cell function and diabetes
- (2019) Carla Perego et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
- (2019) E. Stein et al. ATHEROSCLEROSIS
- Inclisiran Durably Lowers Ldl-C And Pcsk9 Expression In Subjects With Homozygous Familial Hypercholesterolaemia: The Orion-2 Pilot Study
- (2019) F. Raal et al. ATHEROSCLEROSIS
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
- (2019) Amir Abbas Momtazi-Borojeni et al. BMC Medicine
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
- (2018) Ye-Xuan Cao et al. DIABETES OBESITY & METABOLISM
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
- (2018) Andrea Baragetti et al. PHARMACOLOGICAL RESEARCH
- Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
- (2018) Ryo Kawakami et al. PLoS One
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
- (2018) Michel Farnier et al. ATHEROSCLEROSIS
- RNA Therapeutics in Cardiovascular Precision Medicine
- (2018) Ageliki Laina et al. Frontiers in Physiology
- Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
- (2018) Adri M. Galvan et al. JOURNAL OF LIPID RESEARCH
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibodies in Patients Treated with Alirocumab
- (2017) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
- (2017) Andrea Baragetti et al. European Journal of Preventive Cardiology
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
- (2017) Nathanael G. Lintner et al. PLOS BIOLOGY
- Genetic Architecture of Familial Hypercholesterolaemia
- (2017) Mahtab Sharifi et al. Current Cardiology Reports
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
- (2017) Michael J. Koren et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells
- (2016) Derek T. Peters et al. DEVELOPMENT
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese
- (2015) Clara S. Tang et al. Nature Communications
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
- (2014) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
- (2014) Giuseppe Danilo Norata et al. VASCULAR PHARMACOLOGY
- Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice 性别与西方饮食对CSK9基因缺陷的PC57BL/6老龄小鼠的脂质以及葡萄糖内稳态的不同影响
- (2014) Majambu Mbikay et al. Journal of Diabetes
- Targeting PCSK9 for Hypercholesterolemia
- (2013) Giuseppe Danilo Norata et al. Annual Review of Pharmacology and Toxicology
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
- (2013) Giuseppe Danilo Norata et al. EUROPEAN HEART JOURNAL
- Gene silencing approaches for the management of dyslipidaemia
- (2013) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Silencing disease genes in the laboratory and the clinic
- (2011) Jonathan K Watts et al. JOURNAL OF PATHOLOGY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition
- (2011) G. Tibolla et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
- Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
- (2007) Yasuko Miyake et al. ATHEROSCLEROSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now